AnaptysBio (ANAB) Projected to Post Earnings on Monday

AnaptysBio (NASDAQ:ANAB) is expected to announce its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($1.55) per share and revenue of $7.79 million for the quarter.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.89. The business had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Stock Performance

ANAB stock opened at $16.34 on Friday. The company has a market capitalization of $501.10 million, a P/E ratio of -2.69 and a beta of 0.02. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31. The business has a 50-day simple moving average of $16.23 and a two-hundred day simple moving average of $23.99.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright reissued a “neutral” rating and set a $22.00 target price on shares of AnaptysBio in a research report on Tuesday, March 4th. Wolfe Research assumed coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 target price on the stock. Truist Financial dropped their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Wells Fargo & Company lifted their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a report on Wednesday, February 12th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.11.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 65,184 shares of the stock in a transaction on Monday, December 30th. The shares were acquired at an average price of $12.92 per share, with a total value of $842,177.28. Following the acquisition, the director now directly owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. The trade was a 0.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.